Paclitaxel Chemotherapy Elicits Widespread Brain Anisotropy Changes in a Comprehensive Mouse Model of Breast Cancer Survivorship: Evidence From
DTI/DWI
comorbidities
cytokines
fatigue
mammary tumor
survivor
translational
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
12
2021
accepted:
22
02
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Breast cancer is one of the most common diseases in the United States with 1 in 8 women developing the disease in her lifetime. Women who develop breast cancer are often post-menopausal and undergo a complex sequence of treatments including surgery, chemotherapy, and aromatase inhibitor therapy. Both independently and through potential interactions, these factors and treatments are associated with behavioral comorbidities reported in patients (e.g., fatigue), although the underlying neurobiological mechanisms are poorly understood. Currently, brain imaging is the most feasible way to assess neurobiology in patients. Indeed, breast cancer patients display alterations in white matter connections and chemotherapy is associated with decreased white and gray matter in the corpus callosum and cortex as well as decreased hippocampal volume. However, imaging in breast cancer rodent models is lacking, impeding translation of the mechanistic neurobiological findings made possible through modeling. Furthermore, current rodent models of breast cancer often lack the complexity of typical multimodal breast cancer treatments, thereby limiting translational value. The present study aimed to develop a comprehensive model of post-menopausal breast cancer survival using immunocompetent ovariectomized mice, including an orthotopic syngeneic tumor, surgical tumor removal, chemotherapy, and aromatase inhibitor therapy. Using this model, we systematically investigated the cumulative effects of chemotherapy and hormone replacement therapy on neurostructure and behavior using diffusion weighted imaging, open field test, and spontaneous alternation test. Our previous findings, in a simplified chemotherapy-only model, indicate that this regimen of chemotherapy causes circulating and central inflammation concurrent with reduced locomotor activity. The current study, in the more comprehensive model, has recapitulated the peripheral inflammation coincident with reduced locomotor activity as well as demonstrated that chemotherapy also drives widespread changes in brain anisotropy. Validating the clinical relevance of this comprehensive rodent breast cancer model will allow for additional neurobiological investigations of the interactions among various cancer components associated with behavioral comorbidities, as well as the relationship between these mechanisms and neurostructural imaging changes that can be measured in cancer patients.
Identifiants
pubmed: 35402248
doi: 10.3389/fonc.2022.798704
pmc: PMC8984118
doi:
Types de publication
Journal Article
Langues
eng
Pagination
798704Informations de copyright
Copyright © 2022 Otto, Russart, Kulkarni, McTigue, Ferris and Pyter.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arthritis Res Ther. 2018 Feb 7;20(1):21
pubmed: 29415762
Endocr Rev. 1999 Jun;20(3):279-307
pubmed: 10368772
Integr Cancer Ther. 2021 Jan-Dec;20:15347354211019470
pubmed: 34027702
Cereb Cortex. 1994 Mar-Apr;4(2):119-28
pubmed: 8038563
Brain Imaging Behav. 2013 Dec;7(4):374-87
pubmed: 23996156
Brain Imaging Behav. 2018 Apr;12(2):324-334
pubmed: 28290072
Breast Cancer Res Treat. 2012 Apr;132(3):1099-106
pubmed: 22205140
J Clin Oncol. 2008 Feb 10;26(5):768-77
pubmed: 18258985
J Clin Oncol. 2012 Jan 20;30(3):274-81
pubmed: 22184379
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11600-5
pubmed: 23798392
Annu Rev Clin Psychol. 2019 May 7;15:399-423
pubmed: 30786242
Sci Rep. 2019 Nov 11;9(1):16490
pubmed: 31712703
Experientia. 1989 Sep 15;45(9):828-38
pubmed: 2673835
PLoS One. 2013 Nov 01;8(11):e78811
pubmed: 24223850
Methods Mol Biol. 2019;1916:303-309
pubmed: 30535707
J Clin Oncol. 2001 Jul 15;19(14):3385-91
pubmed: 11454886
PLoS One. 2012;7(5):e36956
pubmed: 22615854
J Neurogenet. 1989 Jan;5(1):61-76
pubmed: 2703941
Sleep. 2019 Oct 9;42(10):
pubmed: 31323086
Breast Cancer Res. 2020 May 19;22(1):51
pubmed: 32430040
World J Biol Chem. 2015 Aug 26;6(3):231-9
pubmed: 26322178
PLoS One. 2011;6(10):e25349
pubmed: 22016764
Cancer. 2014 Jun 15;120(12):1854-62
pubmed: 24777606
J Natl Cancer Inst. 2015 Jun 22;107(8):
pubmed: 26101331
Presse Med. 2018 Apr;47(4 Pt 2):e73-e81
pubmed: 29656802
Eur J Cancer. 2006 May;42(7):846-63
pubmed: 16460928
Adv Exp Med Biol. 2015;862:53-75
pubmed: 26059929
Front Immunol. 2019 Jul 19;10:1696
pubmed: 31379879
Brain Behav Immun. 2015 Oct;49:1-17
pubmed: 25958011
Asia Pac J Oncol Nurs. 2020 Mar 30;7(2):134-140
pubmed: 32478130
Front Neuroendocrinol. 2016 Jan;40:87-100
pubmed: 26774208
Support Care Cancer. 2016 Mar;24(3):1097-105
pubmed: 26260726
Cancer Res. 2005 Jun 15;65(12):5439-44
pubmed: 15958593
Nat Immunol. 2020 Nov;21(11):1319-1326
pubmed: 33077953
Cancer. 2009 Nov 15;115(22):5349-61
pubmed: 19753617
PLoS One. 2020 Jul 31;15(7):e0235232
pubmed: 32735618
Cancer. 2018 Oct 15;124(20):3990-3999
pubmed: 29975400
Cytokine. 2004 Feb 7;25(3):94-102
pubmed: 14698135
Dis Model Mech. 2018 Jun 27;11(6):
pubmed: 29752287
Cancer Res. 1978 Oct;38(10):3174-81
pubmed: 210930
Brain Behav Immun. 2022 Jan;99:106-118
pubmed: 34563619
BMC Cancer. 2021 Jul 18;21(1):830
pubmed: 34275458
Cancer. 2013 Jul 15;119(14):2564-73
pubmed: 23633399
Neurobiol Learn Mem. 2004 Nov;82(3):309-23
pubmed: 15464412
J Cancer Surviv. 2009 Dec;3(4):223-32
pubmed: 19760150
AJNR Am J Neuroradiol. 1998 Feb;19(2):217-21
pubmed: 9504468
PLoS One. 2015 May 08;10(5):e0125748
pubmed: 25955025
Neurosci Biobehav Rev. 2013 Sep;37(8):1311-21
pubmed: 23660455
Cancer Res. 1995 Jul 15;55(14):3073-7
pubmed: 7606729
J Neuroimmunol. 2010 Feb 26;219(1-2):90-9
pubmed: 20096467
Cancer Res. 1981 Oct;41(10):3863-7
pubmed: 7284994
JMIR Mhealth Uhealth. 2020 Nov 11;8(11):e22006
pubmed: 33174852
Prog Transplant. 2010 Mar;20(1):58-66; quiz 67
pubmed: 20397348
Invasion Metastasis. 1983;3(1):22-31
pubmed: 6677618
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
J Cancer Surviv. 2010 Sep;4(3):202-9
pubmed: 20401542
Brain Behav Immun. 2013 Nov;34:108-19
pubmed: 23928287
Sci Rep. 2019 Apr 24;9(1):6497
pubmed: 31019214
Behav Brain Res. 2021 Feb 5;399:113041
pubmed: 33279635
Front Immunol. 2020 Feb 21;11:249
pubmed: 32153576
Brain Behav Immun. 2015 Aug;48:195-204
pubmed: 25882911
Behav Brain Res. 2017 Jul 14;330:108-117
pubmed: 28479263
Maturitas. 2017 Sep;103:45-53
pubmed: 28778332
Cancer Res. 1992 Mar 15;52(6):1399-405
pubmed: 1540948
Brain Behav Immun. 2021 Jul;95:401-412
pubmed: 33895287
Indian J Palliat Care. 2012 Sep;18(3):165-75
pubmed: 23439783
Neuroimage Clin. 2015 May 07;8:305-13
pubmed: 26106555
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Front Immunol. 2018 Jun 07;9:1195
pubmed: 29930550
Brain Behav Immun. 2015 Jan;43:76-85
pubmed: 25102452